. Implications for the clinician
Moreover, the right of the subject not to know his / her genetic status should absolutely be respected. Therefore, in 2 .1. Genetic testing as prognostic tool in HCM patients our opinion, a genetic counselling should provide detailed information about the disease and the current medical The main question for a clinician is: Could molecular knowledge in order to clarify both, the potential benefits genetic testing allow to better stratify the prognosis of a and limitations of the genetic testing. given HCM patient? Can it identify a subgroup of patients
In most cases, genetic testing in apparently healthy with a particularly high risk for SCD which might subrelatives will indicate the absence of a mutation, and thus. sequently benefit from invasive therapeutic (and prophylacsubjects will be reassured. In addition, in these negatively tic) strategies, such as an implantable cardioverter detested relatives regular cardiological visits with ECG and fibrillator? The presence of several different disease genes, echocardiography can be stopped, which will result in cost like b myosin heavy chain gene (MYH7), cardiac myosin reductions for the society. In contrast, in relatives with a binding protein C (MYBPC3), cardiac troponin T gene mutation, a strict medical follow-up will be required. This (TNNT2), and others, may result in a different natural will allow to detect the onset of the disease very early and history of the disease. In families related to the MYH7 this will probably lead to improved management. Since gene, the phenotype varies considerably according to the sudden death is often the first symptom of the disease, the mutation. Some mutations were associated with a more early diagnosis of the disease expression in the heart, even malignant prognosis with up to 50% mortality by the age before the occurrence of the symptoms, will lead to a of 40 years (R403Q, R403L, R453C, G716R, R719W and refined cardiac examination and risk stratification including R723G), whereas others have a more benign prognosis exercise test and Holter monitoring. This will allow to (G256E, F513C, V606M, L908V) [2, 8, 11, 12] . In families estimate the individual's (and family's) risk and gives the related to the TNNT2 gene, the phenotype appears to be opportunity to discuss the therapeutic strategy according to similar for the different mutations, and characterised by an the risk stratification (for example, implantation of a incomplete penetrance (75%), a relatively mild and somecardioverter defibrillator [17] ). times subclinical hypertrophy (mean 1765 mm) but a high
In addition, pre-symptomatic diagnosis might result in incidence of sudden death before 30 years-of-age [13] . In additional benefit in selected cases. In teenagers planning families related to the MYBPC3 gene, the phenotype to become an athlete or individuals with high physical appears also similar for the different mutations and charactivity in their profession, genetic testing may help them acterised by both, a low penetrance (41%), a low degree of to decide for their future professional activity. If a mutahypertrophy before 30 years-of-age (mean 1264 mm), a tion could be identified and LV hypertrophy (cardiac delayed age at onset of symptoms, and a favourable expression of the disease) is present, physical activity prognosis before 30 years-of-age [11, 12, 14] . All of these restriction will be anticipated. In the case of mutation results could be particularly useful for the purpose of risk detection and absence of LV hypertrophy, it remains stratification in HCM patients and for leading to a better subject to discussion as to whether physical activity clinical management. However, caution is required and restriction should be advised (in case of numerous premafurther studies based on large populations are needed to ture cardiac deaths in the family, this advise appears confirm these data since available studies were performed reasonable [16] ). in small populations, data were usually retrospective, and some exceptions to these correlations have been reported 2 .3. Genetic testing as a diagnostic tool [15] .
In a patient with LV hypertrophy, it is sometimes 2 .2. Pre-symptomatic genetic testing in relatives of difficult to diagnose correctly HCM as the cause of LV HCM patients hypertrophy (especially when hypertrophy is symmetric, and when the familial context of a cardiac disease is When a disease causing mutation was identified in the absent). In these cases, it may be useful to characterise the index patient of the family, the genetic testing in family molecular cause, so that the therapeutic strategy could be members is very efficient as compared to a cardiological better defined. Indeed, specific therapeutics are required in screening. This has also been shown in the present paper other rare causes of LV hypertrophy, such as Fabry disease by Havndrup et al. [1] . However, what is the potential or cardiac amyloidosis. Moreover, in a patient with an benefit of the procedure? At present, for mutation carriers apparently sporadic form of HCM, it may be useful to there is no therapy available which could reverse or determine the genetic origin of the disease, in order to prevent the development of the disease. Moreover, identifidetermine the risk of transmitting the disease to offspring. cation of a mutation through a pre-symptomatic screening may result in an adverse psychological effect (to be certain 2 .4. Genetic testing as a prenatal diagnosis to be at risk for major complications) and may additionally have also adverse outcomes (social, occupational, and Sometimes, prenatal diagnosis is requested by parents insurance matters) [16] .
who have a high incidence of SCD in one of their families, and who carry, therefore, a high psychosocial burden. To and expanded before to be applied and recommended in perform such a prenatal procedure implies that the couple clinical practice. In order to see clear differences in clinical wants to draw practical conclusions from the testing, i.e., expression (e.g. LV hypertrophy, survival, SCD) between to possibly perform a pregnancy termination if the foetus the different mutations in the different genes, the power of has the mutation. This prenatal testing is, however, depenthe statistics is critical and therefore large numbers need to dent on the knowledge of the mutation in this family. If the be included. At present, however, it is not possible to mutation is not known, the prenatal testing will be clinically examine a HCM patient (or a HCM family) and probably be ineffective, because currently the speed to to deduce the disease gene from the phenotype (in the detect an unknown mutation is slower than necessary to present paper, in only 13% of all HCM patients a mutation terminate a 'carrier' pregnancy. Therefore, at present and in the MYH7 gene was found). In this respect, it may be from a medical point of view, the prenatal testing proimaginable to enter and to follow-up members of HCM cedure can not be recommended in most cases due to the families in a large database, possibly world wide. Such an variable and mostly benign prognosis of the disease [16] .
effort has been achieved in part for cataloguing all HCM In selected cases, however, the prenatal testing can be mutations (http: / / morgan.angis.su.oz.au / Databases / Heart / discussed, especially when the family history is characterheartbreak.html). Furthermore, detailed and prospective ised by numerous premature cardiac deaths [18] .
analyses of large HCM cohorts will be necessary to unravel the presence and importance of genes that modify the phenotype (so-called modifier genes).
. Implications for the molecular biologist
Concerning the medical counselling of the patients, it will be wise to install a specific and multidisciplinary The molecular screening of several HCM causing genes approach to ensure good medical practice [16] . This is feasible. Since there is both, locus (different genes make counselling should include a cardiologist, a geneticist and the same disease) and allelic (different mutations in one a psychologist, and should meet the following requiregene) heterogeneity, the screening is very time and costments: (1) the subject or the family should be counselled consuming. In the study by Havndrup et al. [1] , in only in advance for the potential benefit and the limitations of 13% of HCM index cases a mutation in the MYH7 gene the test; (2) the genetic counselling should always precede could be identified. For this low identification rate there are the blood sampling, which results solely from the decision some possible explanations: (1) the MYH7 gene accounts by the applicant; and (3) confidentiality of the procedure for the genetic cause of |30-50% of all HCM families must be granted. If these practices can be accepted, we can (MyBPC3 |30-50% and all other genes |10%) and be confident and hope that molecular genetics will result in Havndrup et al. screened only exons 3-23 of the MYH7 an improvement of the quality of life of HCM patients and gene; (2) the sensitivity of the screening method (single their families. In the next few years, fast and less expenstrand conformation polymorphism, SSCP) is usually only sive mutation detection techniques, like chip-based seabout 70 to 90% (performed with two temperatures at 4 quencing, are on the horizon. These techniques will allow and 20 8C), thus, some mutations might have been missed; a fast and cost-effective mutation detection in the clinical and (3) sporadic and familial forms of HCM were mixed routine. and sporadic HCM cases are possibly less related to a genetic cause. In addition, double mutations (double heterozygous subjects) were found in the paper of R eferences Havndrup et al. [1] , although the pathogenic role of the MYBPC3 variant was not certain. This finding, and with HCM, even when a (first) mutation is identified.
